Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study (vol 59, pg 239, 2024)

被引：0
|
作者：
Ogawa, Eiichi
Jun, Dae Won
Toyoda, Hidenori
Hsu, Yao-Chun
Yoon, Eileen L.
Ahn, Sang Bong
Yeh, Ming-Lun
Do, Son
Trinh, Huy N.
Takahashi, Hirokazu
Enomoto, Masaru
Kawada, Norifumi
Yasuda, Satoshi
Tseng, Cheng-Hao
Kawashima, Keigo
Lee, Han Ah
Inoue, Kaori
Haga, Hiroaki
Do, Ai-Thien
Maeda, Mayumi
Hoang, Joseph H.
Cheung, Ramsey
Eguchi, Yuichiro
Ueno, Yoshiyuki
Furusyo, Norihiro
Yu, Ming-Lung [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Tanaka, Yasuhito
Nguyen, Mindie H.
机构：
[1] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan
[2] Kaohsiung Med Univ, Coll Med, Hepatitis Res Ctr, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ, Cohort Res Ctr, Kaohsiung, Taiwan
[4] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan
[5] Natl Sun Yat Sen Univ, Sch Med, Kaohsiung, Taiwan
[6] Natl Sun Yat Sen Univ, Coll Med, Doctoral Program Clin & Expt Med, Kaohsiung, Taiwan
[7] Natl Sun Yat Sen Univ, Ctr Excellence Metab Associated Fatty Liver Dis, Kaohsiung, Taiwan
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2024年 / 59卷 / 05期
关键词：
D O I：
10.1111/apt.17885
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：725 / 725
页数：1
相关论文
共 50 条
  • [41] Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B
    Kahraman, Resul
    Sahin, Abdurrahman
    Ozturk, Oguzhan
    Calhan, Turan
    Sayar, Suleyman
    Kanat, Evren
    Doganay, Levent
    Ozdil, Kamil
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2022, 33 (01): : 35 - 43
  • [42] EFFECTIVENESS AND SAFETY OF 48-WEEK TENOFOVIR AMIBUFENAMIDE VS TENOFOVIR ALAFENAMIDE FUMARATE FOR PATIENTS WITH CHRONIC HEPATITIS B: A RETROSPECTIVE REAL-WORLD STUDY
    Zeng, Qing-Lei
    Chen, Ru-Yue
    Lv, Xue-Yan
    HEPATOLOGY, 2024, 80 : S312 - S312
  • [43] BONE MINERAL DENSITY LOSS IN TENOFOVIR TREATED CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IS A CONSEQUENCE OF VITAMIN D DEFICIENCY AND NOT TENOFOVIR THERAPY
    Gill, U. S.
    Al-Shamma, S.
    Burke, K.
    Ross, V.
    Marley, R. T. C.
    Kooner, P.
    Foster, G. R.
    Kennedy, P. T. F.
    GUT, 2011, 60 : A28 - A28
  • [44] BONE MINERAL DENSITY LOSS IN TENOFOVIR TREATED CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IS A CONSEQUENCE OF VITAMIN D DEFICIENCY AND NOT TENOFOVIR THERAPY
    Gill, Upkar
    Al-shamma, Safa
    Burke, Katherine B.
    Ross, Valerie A.
    Marley, Richard
    Kooner, Paul
    Foster, Graham R.
    Kennedy, Patrick T.
    HEPATOLOGY, 2011, 54 : 1012A - 1012A
  • [45] Safety of tenofovir alafenamide administered before or in early phase of pregnancy in women with active chronic hepatitis B and the effectiveness in preventing perinatal hepatitis B virus infection: a multicenter prospective study
    Zeng, Qing-Lei
    Li, Guangming
    Feng, Ying-Hua
    Zhang, Guofan
    Li, Wei
    Xu, Jiang-Hai
    Li, Zhi-Qin
    Zhou, Yi-Hua
    Yu, Zu-Jiang
    JOURNAL OF HEPATOLOGY, 2021, 75 : S740 - S741
  • [46] WEEK 96 EFFICACY AND SAFETY RESULTS OF TENOFOVIR ALAFENAMIDE (TAF) COMPARING TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B (CHB), HBEAG-NEGATIVE, CHRONIC HEPATITIS B PATIENTS: A GLOBAL PHASE 3 STUDY
    Brunetto, Maurizia Rossana
    Lim, Young-Suk
    Gane, Edward
    Seto, Wai-Kay
    Osipenko, Marina
    Ahn, Sang Hoon
    Janssen, Harry L.
    Shukla, Akash
    Chuang, Wan-Long
    Trinh, Huy N.
    Celen, Mustafa
    Flaherty, John F.
    Chan, Alain
    Lau, Audrey
    Gaggar, Anuj
    Suri, Vithika
    Subramanian, Mani
    Pan, Calvin Q.
    Izumi, Namiki
    Marcellin, Patrick
    Chan, Henry L.
    Buti, Maria
    GASTROENTEROLOGY, 2017, 152 (05) : S1086 - S1086
  • [47] A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96
    Brunetto, M.
    Lim, Y. S.
    Gane, E.
    Seto, W. K.
    Osipenko, M.
    Ahn, S. H.
    Janssen, H. L.
    Shukla, A.
    Chuang, W. L.
    Trinh, H.
    Celen, M. K.
    Flaherty, J. F.
    Lau, A. H.
    Gaggar, A.
    Suri, V.
    Bhardwaj, N.
    Kim, K.
    Subramanian, G. M.
    Pan, C.
    Izumi, N.
    Marcellin, P.
    Chan, H.
    Buti, M.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S25 - S26
  • [48] A PHASE 3 STUDY OF TENOFOVIR ALAFENAMIDE COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HBEAG-NEGATIVE, CHRONIC HEPATITIS B: WEEK 48 EFFICACY AND SAFETY RESULTS
    Buti, M.
    Gane, E.
    Seto, W. K.
    Chan, H. L. Y.
    Chuang, W. -L.
    Stepanova, T.
    Hui, A. J.
    Lim, Y. -S.
    Mehta, R.
    Janssen, H. L. A.
    Acharya, S. K.
    Flaherty, J. F.
    Massetto, B.
    Cathcart, A.
    Dinh, P.
    Subramanian, G. M.
    McHutchison, J. G.
    Pan, C.
    Brunetto, M.
    Izumi, N.
    Marcellin, P.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S135 - S136
  • [49] FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT?
    Gill, U. S.
    Al-Shamma, S.
    Burke, K.
    Ross, V.
    Kooner, P.
    Marley, R.
    Foster, G. R.
    Kennedy, P. T. F.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S286 - S286
  • [50] FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT?
    Gill, U. S.
    Al-Shamma, S.
    Burke, K.
    Ross, V.
    Marley, R.
    Kooner, P.
    Foster, G. R.
    Kennedy, P. T. F.
    GUT, 2011, 60
12345